New drug combo shows promise for Hard-to-Treat brain cancer
NCT ID NCT04462328
First seen Mar 18, 2026 · Last updated May 12, 2026 · Updated 5 times
Summary
This early-phase study tests a combination of two drugs (acalabrutinib and durvalumab) for people with primary central nervous system lymphoma, a rare brain cancer. The study includes up to 25 patients whose cancer has returned or who cannot receive standard chemotherapy. The main goal is to find a safe dose and check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Ohio State University Hospital
Columbus, Ohio, 43210, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.